Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1797MR)

This product GTTS-WQ1797MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1797MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4805MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ6629MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ13650MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ13312MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ6679MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ11744MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ2582MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ15603MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW